Galante Joseph C 4
4 · CUMBERLAND PHARMACEUTICALS INC · Filed Dec 23, 2022
Insider Transaction Report
Form 4
Galante Joseph C
Director
Transactions
- Purchase
Common Stock
2022-11-02$2.54/sh+65$165→ 54,571 total - Purchase
Common Stock
2022-11-03$2.44/sh+65$159→ 54,636 total - Purchase
Common Stock
2022-11-07$2.45/sh+65$159→ 54,766 total - Purchase
Common Stock
2022-11-01$2.53/sh+65$164→ 54,506 total - Purchase
Common Stock
2022-11-04$2.42/sh+65$157→ 54,701 total - Purchase
Common Stock
2022-11-08$2.42/sh+65$157→ 54,831 total - Purchase
Common Stock
2022-11-10$2.37/sh+65$154→ 54,961 total - Purchase
Common Stock
2022-11-17$2.29/sh+65$149→ 55,286 total - Purchase
Common Stock
2022-11-18$2.27/sh+65$148→ 55,351 total - Purchase
Common Stock
2022-11-21$2.38/sh+65$155→ 55,416 total - Purchase
Common Stock
2022-11-23$2.29/sh+65$149→ 55,546 total - Purchase
Common Stock
2022-11-28$2.37/sh+65$154→ 55,676 total - Purchase
Common Stock
2022-11-29$2.34/sh+65$152→ 55,741 total - Purchase
Common Stock
2022-11-30$2.32/sh+65$151→ 55,806 total - Purchase
Common Stock
2022-11-15$2.35/sh+65$153→ 55,156 total - Purchase
Common Stock
2022-11-16$2.31/sh+65$150→ 55,221 total - Purchase
Common Stock
2022-11-25$2.31/sh+65$150→ 55,611 total - Purchase
Common Stock
2022-11-09$2.37/sh+65$154→ 54,896 total - Purchase
Common Stock
2022-11-11$2.32/sh+65$151→ 55,026 total - Purchase
Common Stock
2022-11-14$2.32/sh+65$151→ 55,091 total - Purchase
Common Stock
2022-11-22$2.37/sh+65$154→ 55,481 total
Footnotes (1)
- [F1]The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022.